The aim of our study was to assess the cumulative incidence and severity ('burden') of late effects in a single-centre cohort of childhood haematopoietic stem cell transplantation (HSCT) survivors, at least 2 years after transplantation. The presence and severity of late effects in each survivor was documented according to the Common Terminology Criteria for Adverse Events (version 3.0). The burden of late effects was graded from mild to disabling/life-threatening. Risk factors for a high burden of late effects were assessed by univariate and multivariate logistic regression analyses. Among 162 survivors of HSCT seen in our late effects outpatient clinic, cumulative incidence of late effects was 93.2% after a median followup time of 7.2 years (range 2.0-21.0 years) after HSCT. The burden of late effects was mild, moderate, severe and disabling in 28, 41, 24 and 1% of survivors respectively. Risk factors for a severe or disabling burden of late effects were older age at HSCT (P for trend o0.001) and a conditioning regimen including irradiation OR 2.2, 95% CI 1.1-4.7, P ¼ 0.03). In conclusion, a high burden of late effects is found in childhood HSCT survivors after a median follow-up of only 7 years.
Introduction
In 1968, the first BMT in Europe was performed in a child with combined immune deficiency in our department in Leiden. 1 Till January 2008, 727 allogeneic haematopoietic stem cell transplantations (HSCT) in 652 children have been performed in our unit. Our overall survival rate at 2 years post transplant is currently 65.4% (unpublished data).
Although HSCT may provide a cure for both malignant and non-malignant diseases and is mostly the only viable option for cure of the underlying disease, this cure comes at a price. The high-dose chemotherapy and/or radiotherapy used in the conditioning regimen for HSCT as well as transplant-related complications are associated with organ toxicity that may impair the long-term health of these patients. Most children who undergo HSCT for a malignancy have received treatment for their disease before HSCT. The addition of the conditioning regimen for HSCT and of transplant-related morbidity is likely to increase the risk for late effects as compared to children treated for cancer without HSCT.
Two important studies on the 'burden' of late effects in childhood cancer survivors, with a median follow-up of 25 and 17 years, respectively, have been published. 2, 3 The cumulative incidence of late effects in childhood cancer survivors was shown to be 73 and 75% respectively. Fortytwo per cent and 40% of survivors had severe, disabling and/or life-threatening late effects or died due to an adverse effect of cancer treatment. 2, 3 Two reviews on late effects of HSCT in childhood have been published, which highlighted the broad variety of late effects, both endocrine and non-endocrine, in childhood HSCT survivors. [4] [5] [6] Only a few studies have been published on the cumulative incidence and severity or 'burden' of late effects in survivors of childhood HSCT. These studies have focused on survivors with a particular disease, age and/or conditioning regimen, for example including TBI. [7] [8] [9] [10] The aim of our study was to assess the cumulative incidence and severity of late effects, together representing the 'burden of late effects', in childhood HSCT survivors in our centre. All diseases, donor and stem cell sources, and conditioning regimens were included and patients were all seen in follow-up at our outpatient Paediatric Late Effects (LE) clinic according to a pre-defined protocol. In addition, risk factors for a high burden of late effects in this cohort were assessed.
Patients and methods

Design and study population
We performed a cohort study among all patients who underwent HSCT in our Paediatric (ageo18 years) unit. Patients who were alive at least 2 years after HSCT and were seen in our Paediatric LE Outpatient Clinic until January 2008 were eligible for this study. The LE clinic started in November 2001 and both childhood cancer survivors more than 5 years after treatment and survivors of HSCT at least 2 years after transplant are seen in this clinic on a yearly basis.
Of 332 childhood HSCT survivors that were alive at least 2 years after transplant, 162 survivors were seen in the clinic and were included in the study. These children were all seen by a paediatric haemato-oncologist specialized in late effects and were assessed according to pre-defined local and national guidelines for late effects follow-up. At their visit to the clinic an extensive questionnaire on all types of health problems was completed and physical examination was performed. Blood samples and urine samples were taken for complete blood count, chemistry and endocrine evaluation. Echocardiography and pulmonary function tests (PFTs) were performed and children who received irradiation to the eye were seen by an ophthalmologist on at least one occasion. All children who had TBI were also seen by a paediatric endocrinologist. In the non-irradiated group, endocrine function was assessed by the paediatric haemato-oncologist. Although designated a Paediatric LE clinic, a few young adult survivors of HSCT were evaluated at least once, either on their own specific request or because they were already 16 years or older at the time of transplant.
A total of 170 patients alive at least 2 years after childhood HSCT were not seen in the Paediatric LE clinic for the following reasons: 88 patients were older than 18 years at the time the clinic started, 15 children had not yet been transferred from the HSCT outpatient clinic to the LE clinic, 45 children visited a late effects clinic in the Paediatric University Centre where they were treated for their disease before HSCT in our centre, 13 patients lived abroad and 6 patients were lost to follow-up. Three patients died more than 2 years after HSCT and before entry in the LE clinic, all due to their underlying disease.
Clinical data collection
All childhood HSCT survivors had the following data collected: sex, age at HSCT, date of last follow-up, disease for which HSCT was performed, donor type and stem cell source, and conditioning regimen. The diseases were grouped into four entities: (1) haemato-oncological disease: ALL, AML, chronic myeloid leukaemia, Juvenile myelomonocytic leukaemia (JMML), myelodysplastic syndrome, anaplastic large cell lymphoma (ALCL); (2) (non-malignant) haematological disease: (severe) aplastic anaemia, Fanconi anaemia, Blackfan Diamond anaemia, congenital amegakaryocytic thrombocytopenia, thalassaemia; (3) immunological disease: (S)CID, CID, Omenn syndrome, Wiskott-Aldrich syndrome, X-linked lymphoproliferative disease, Chediak Higashi, haemophagocytic lymphohistiocytosis (HLH) and (4) other inborn errors of metabolism: osteopetrosis, X-adrenoleukodystrophy, metachromatic leukodystrophy. Donor type was defined as matched sibling donor (MSD), matched/mismatched unrelated donor and other related donor (including both a haploidentical parent and HLA-matched relatives apart from sibs). The conditioning regimen depends on the disease and many different regimens were administered over time. Therefore, patients were assigned to either of three groups: (1) all regimens including (unfractionated) TBI (age 2-3 years: 7 Gy, 4-9 years: 7.5 Gy and 410 years: 2 Â 6 Gy) or thoraco-abdominal irradiation (TAI: 4-5 Gy); (2) all regimens including BU (16-20 mg/kg) and CY (120-200 mg/kg) with or without other cytotoxic drugs, but no irradiation; (3) other regimens, including reduced intensity conditioning.
Assessment and severity grading of late effects In the 162 childhood HSCT survivors eligible for this study, cumulative incidence and severity of late effects were assessed. Late effects were documented according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (www.fda.gov/cder/cancer/toxicityframe.htm), but scored either per organ involved or as a 'general' late effect not confined to a particular organ. With the CTCAE both acute adverse effects and late adverse effects can be scored and incidence and severity of late effects in different patient groups can thus be compared. The CTCAE has been applied successfully in several studies to establish the burden of late effects in childhood cancer survivors. 2, 3 To the best of our knowledge, so far these criteria have not been applied in studies on late effects after HSCT.
In this study late effects of the following 'organs' and general late effects were scored:
Endocrine disorders (scored as four separate endocrine 'organs') 1. thyroid dysfunction; 2. growth hormone deficiency and/or stunted growth; 3. gonadal dysfunction and/or infertility; 4. adverse effects on bone, that is osteoporosis, osteonecrosis, osteochondroma;
5. cardiac dysfunction; 6. pulmonary function disorder; 7. renal dysfunction (glomerular or tubular; scored as one organ involvement); 8. liver dysfunction; 9. ocular problems; 10. hearing problems; 11. dental/mouth problems; 12. skin problems/alopecia; 13. fatigue; 14. obesity; 15. iron overload; and 16. secondary malignancy.
Because neurotoxicity, neurocognitive and psychological late effects were not investigated in our LE clinic according to a pre-defined protocol, these were not included in the cumulative incidence of late effects.
The severity of a late effect was graded from 0 to 5 according to the CTCAE criteria: grade 1 is mild, 2 is moderate, 3 is severe, 4 is disabling or life-threatening and 5 is death related to adverse effect.
In our study group we defined the 'burden of late effects' in each patient both by the number of organs involved (as defined above) and by the severity of each late effect according to the CTCAE, as follows: related to late effects A few minor adjustments were made to the CTCAE severity grading. It is common practice in our centre to treat children with asymptomatic, compensated hypothyroidism with thyroid hormone replacement therapy and these children were scored as grade 1 hypothyroidism ('asymptomatic'). Gonadal dysfunction/infertility can only be assessed in survivors who have reached puberty or are old enough to be diagnosed with delayed puberty. Because semen analysis is seldom performed in under age boys, we included elevated follicle-stimulating hormone (FSH; 410 U/l) as a grade 1 reproductive/gonadal function toxicity ('asymptomatic'). In our centre it is customary to assess total lung capacity (TLC) instead of (forced) vital capacity as a measure of restrictive lung disease, and TLC as a percentage of predicted value was scored with the same grading for severity. To grade obesity in children, the reference values for body mass index compatible with 25 and 30 kg/m 2 in adults according to Cole et al. 11 were used. Grade 3 was defined as X30 (grade 4 was not scored separately).
Dental problems were assessed by the questionnaire, but 40 HSCT survivors were also included in an ongoing ethical-committee-approved study, which included dental panoramic radiographs (PRG) and dental examination by a trained paediatric dentist with special attention to hypoplasia of elements and roots.
Statistical analyses
Differences in clinical characteristics between the HSCT survivors eligible for the study and survivors not included in the study were assessed with Pearson's w 2 -test. We assessed risk factors for a high burden of late effects (severe or disabling/life-threatening burden of late effects) with univariate and multivariate logistic regression analyses. The following risk factors were analysed: sex, age at HSCT, duration of follow-up, disease, conditioning regimen, stem cell donor, stem cell source and chronic GVHD (cGVHD). Table 1 shows the characteristics of both the childhood HSCT survivors who visited our LE clinic (n ¼ 162) as well as the survivors who could not be assessed for late effects (n ¼ 170). Median age at HSCT in the study group was 6.3 years, 63% were male, and the majority underwent HSCT for a haematological malignancy (54%) and with BM (90%) from an MSD (50%). Of 56 patients with ALL, AML or ALCL, 33, 22 and 1 were transplanted in CR 1, CR 2 and CR 3 respectively. Half of the patients were treated with a conditioning regimen including either TBI or TAI. Median age at HSCT was significantly lower in HSCT survivors included in this study as compared to HSCT survivors who could not be included (Po0.0001; see Patients and methods). Study patients were more likely to have been transplanted with an unrelated donor (P ¼ 0.002). Otherwise the two survivor groups are comparable.
Results
Clinical characteristics of study population
Only 56 of 162 study patients had been treated with intensive combination chemotherapy, but not with radiotherapy, for leukaemia or lymphoma before the HSCT High burden of late effects after HSCT in childhood D Bresters et al procedure. Low doses or short courses of chemotherapy had been given to children with JMML and HLH (8 and 5 respectively) before HSCT. Of the HSCT survivors, 93 (57%) had not been treated with chemotherapy before HSCT.
Cumulative incidence of late effects
The cumulative incidence of late effects in childhood HSCT survivors treated in our centre was 93.2% (151 of 162). Only 11 children had no late effects. The number of late effects in survivors is shown in Figure 1 . Ninety-four survivors (58.0%) had 1-3 late effects, 51 survivors (31.5%) had 4-6 late effects and 6 survivors (3.7%) had at least 7 late effects. Fifteen children (9.3%) had cGVHD. Late effects with the highest cumulative incidence in childhood HSCT survivors were pulmonary late effects, endocrine late effects, that is gonadal dysfunction/infertility, impaired growth with or without growth hormone deficiency, hypothyroidism and dental late effects.
Of 139 patients who underwent a PFT, 113 (81%) had pulmonary toxicity, which was of grade 1 or 2 in all but 3 patients. In children aged 7 years or younger PFT could not be performed.
Gonadal function can only be assessed in children who have reached puberty or pubertal age and 60 of 76 (79%) (post-)pubertal survivors of HSCT had impaired gonadal function/infertility including 28 boys with elevated FSH in whom semen analysis had not yet been performed.
Growth impairment with height beyond two s.d. of age and gender mean height was present in 58 of 162 (35.8%) survivors. In 26 of these survivors growth hormone treatment was started, either for proven GH deficiency or neurosecretory dysfunction. Of these 58 survivors, 11 had diseases known to be associated with growth impairment: Fanconi anaemia (6), dyskeratosis congenita/SAA (1), osteopetrosis (1), Blackfan Diamond anaemia (2) and cartilage hair hypoplasia/SCID (1).
Of 159 survivors in whom thyroid function was tested, 45 (28%) had thyroid dysfunction, namely hypothyroidism in all but one.
Among 146 survivors in whom dental status was recorded, either from the questionnaire or by extensive dental examination in 40 patients participating in a local study, 61 (42%) patients, including 39 patients who had a PRG, were shown to have dental late effects, mainly hypoplasia of elements and/or roots. In three of these survivors dental problems were at least in part due to their primary disease, that is osteopetrosis.
Burden of late effects
The burden of late effects in our survivor group is shown in Table 2 . A total of 47 grades 3 or 4 late effects were found in 40 patients (25% of the study group). The most frequent grade 3 or 4 late effect was gonadal dysfunction with either premature ovarian failure/no sexual development by age 14 years in girls or azoospermia in boys (in 20 survivors, 4 boys). Semen analysis had been performed in only four boys. No death related to late effects was seen.
Risk factors for late effects
In univariate logistic regression analysis female gender was a risk factor for severe or disabling/life-threatening burden of late effects. However, as grade 3 (severe) gonadal toxicity/infertility could be assessed in pubertal girls, but semen analysis was only performed in four boys, we analysed gender as a risk factor after excluding gonadal late effects. The results of this analysis showed that gender was no longer a risk factor for high burden of late effects.
We found older age at time of transplant to be a risk factor (P for trend o0.001) for severe or disabling/lifethreatening burden of late effects. In multivariate analysis, with diagnosis and conditioning regimen included, older age was still a risk factor. After exclusion of gonadal late effects, older age at HSCT is still a risk factor, but not in multivariate analysis including TBI/TAI as a covariate.
A conditioning regimen including TBI/TAI was also a significant independent risk factor for severe or disabling/ life-threatening burden of late effects (OR 2.2, confidence interval (CI) 1.1-4.7, P ¼ 0.029). This was still true if gonadal late effects were excluded.
Although survivors who had cGVHD were more likely to have a high burden of late effects, only 15 survivors had cGVHD and thus the power was insufficient to analyse cGVHD as a risk factor for more severe late effects.
Follow-up time, diagnosis in four subgroups, donor type and stem cell source were not found to be risk factors for a high burden of late effects by logistic regression analysis. However, the low number of survivors in some groups hampered statistical analysis. High burden of late effects after HSCT in childhood D Bresters et al
Discussion
Our study shows that after a median follow-up of 7 years after transplant almost all childhood HSCT survivors (93%) have one or more late effects. In 40 of 162 (25%) childhood HSCT survivors, the burden of late effects was considered severe or disabling/life-threatening. Less than half of the patients had received intensive chemotherapy before the HSCT procedure. Nevertheless, the cumulative incidence of late effects in childhood HSCT survivors was higher than has been described in childhood cancer survivors. In the latter group a cumulative incidence of late effects of 75% at a median of 17-25 years after treatment was found and 40% were shown to have severe, disabling or life-threatening late effects. 2, 3 In our study 25% of survivors had severe late effects, but after a followup of only 7 years. With longer follow-up, the cumulative incidence and severity of late effects in our study group are likely to increase further, because many late effects are known to occur with a long latency after treatment, such as cataract after TBI and secondary malignancies. In this study only one secondary malignancy was observed, a melanoma in a 16-year-old survivor with cGVHD. It is well known that HSCT is a risk factor for the development of secondary malignancies and the cumulative incidence rises steeply with time after HSCT. [12] [13] [14] [15] [16] Follow-up and assessment of late effects in adult survivors of HSCT in childhood is of the utmost importance to obtain an indepth knowledge of HSCT-induced late effects. Unfortunately, an adult late effects clinic has not yet started in our hospital, but is expected to be implemented in the near future.
Despite a high cumulative incidence of late effects, our impression is that the quality of life of these children is good. Most children have returned to school full time, participate in sports as do their siblings and experience no limitations in their daily activities. However, further studies are ongoing to assess the quality of life of our childhood HSCT survivors.
The most prevalent late effect in HSCT survivors is pulmonary toxicity, but this was asymptomatic, grade 1 or 2 according to the CTCAE, in most children. Pulmonary dysfunction after HSCT has been described and may occur especially in children with BU or TBI as part of the conditioning regimen. [17] [18] [19] [20] [21] The second most prevalent late effect was endocrine toxicity, involving growth, gonadal function/infertility and hypothyroidism. Endocrine late effects are more common in HSCT survivors who had TBI/TAI as part of their conditioning regimen, but gonadal dysfunction and infertility is also highly prevalent after conditioning regimens with a combination of alkylating cytotoxic drugs (BU, CY, melphalan (Mel)). 6, [22] [23] [24] [25] [26] [27] In this study, of 20 survivors with gonadal toxicity grade 3 (16 girls, semen analysis only performed in 4 boys) 10 underwent conditioning including TBI/TAI, 6 conditioning with BU/CY/Mel and 4 with BU/ CY but no Mel.
In a study among 40 survivors on dental late effects running concurrently, 39 children were diagnosed with hypoplasia of elements and/or roots seen on a PRG. Also excessive caries and dry mouth was found in 13 of these 40 children (2 of 13 children with dry mouth had cGVHD). 28 A conditioning regimen including irradiation either as TBI or TAI proved to be a risk factor for a higher burden of late effects. This has also been found in other studies. [4] [5] [6] 10 All children included in this study received single-fraction TBI, but this has recently been replaced by a fractionated regimen in which 2 Gy twice daily for 3 days is given. The main reason for this change in TBI regimen is to lower the risk for late effects and improve the quality of life in survivors. [4] [5] [6] 10, 29, 30 Also, ALL is currently the only disease for which TBI is included in the conditioning regimen, whereas in the past many children with other haematological malignancies have undergone TBI. TAI is no longer applied in our centre.
We found that older age at HSCT in childhood is a risk factor for more severe late effects. This is in agreement with the study by Oeffinger et al. 2 in childhood cancer survivors, in which survivors who received the diagnosis at an older age were significantly more likely to report late effects. Also, it has been shown that the risk for ovarian failure is higher in girls, either after chemotherapy or irradiation, who are post-pubertal at the time of treatment as compared to those who are pre-pubertal. [31] [32] [33] In our study, older age remains a risk factor for a higher burden of late effects even after exclusion of gonadal late effects. This is probably explained by a higher frequency of conditioning including TBI/TAI in older children.
This study has some limitations. Only half of the longterm survivors of childhood HSCT in our centre were included in this study, mainly due to the fact that a late effects outpatient clinic exists for children, but not for adults. The study patients were significantly younger at HSCT as compared to the HSCT survivors that were excluded from the study, for which we do not have an explanation. Also, study patients differed from the excluded HSCT survivors in that they were more often transplanted with an unrelated donor. This can be explained by the fact that in the earlier era, when the excluded HSCT survivors were transplanted, for some diseases HSCT was only considered feasible with an HLA-identical sibling donor. Older age at HSCT was found to be a risk factor for a higher burden of late effects, but donor type was not. Because the two groups are otherwise comparable, especially regarding disease and conditioning regimen, we do feel that our study group is a good reflection of childhood HSCT survivors in our centre. Owing to the inclusion of children only in this study, the duration of follow-up was relatively short. In the future we hope to extend the study to adult survivors of childhood HSCT and thereby increase follow-up time.
We decided to score the late effects per organ system and have excluded some late effects, mainly neurological and neuropsychological late effects, because we had not assessed these late effects objectively according to a relevant follow-up protocol. It is important that these late effects are assessed in the near future, because several studies have shown neuropsychological late effects after childhood HSCT. [34] [35] [36] The scoring per organ system and the omission of some late effects may have led to an underestimation rather than an overestimation of the cumulative incidence of late effects.
Because we decided to include all diagnoses, conditioning regimens and age groups, the number of children in each group was sometimes rather small which has hampered our risk factor analysis. Owing to the small patient number with cGVHD we were not able to assess this as a risk factor for more severe late effects.
Importantly, all children and their parents were seen in the LE clinic on a regular basis by a specialized paediatric haemato-oncologist and had a full medical assessment through which late effects could be assessed objectively and including subclinical late effects. This is in contrast with some other published studies that were based on patient reported (by a mailed questionnaire) late effects. The Dutch Late Effects Working Party (LATER) of the Dutch Childhood Oncology Group has developed evidence-based guidelines for follow-up and screening for late effects in childhood cancer survivors and the use of these guidelines in our late effects clinic has proven invaluable for the assessment of adverse effects of treatment.
In conclusion, our study shows that childhood HSCT survivors have a high cumulative incidence of late effects that warrants lifelong follow-up on a regular basis by specialized doctors and according to evidence-based guidelines. Quality of life in HSCT survivors is likely to be improved by timely intervention and treatment of late effects. Follow-up should continue into adulthood and both the survivors themselves and the doctors involved in their care, such as family doctors, should be educated on the broad range of late effects that may occur and the possibilities of intervention.
